$INBX News
Last published 4w ago
- 4w agoINBXInhibrx Announces Participation in Upcoming Scientific ConferencesPR NewswireSAN DIEGO, Oct. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel
- 2mo agoINBXInhibrx Presents Phase 2 Randomized Data for INBRX-106 in First-Line HNSCC - INHIBRX BIOSCIENCES INCEarnings Call TranscriptsGood morning, everyone, and thank you for joining us for today's Inhibrix Presents Phase 2 Randomized Data for InBrix 106 in FirstLine HNSCC. As a reminder, today's conference is being recorded and all lines are in a mut
- 2mo agoINBXInhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudyPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad...
- 2mo agoINBXInhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC StudyPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad...
- 3mo agoINBXInhibrx Reports Second Quarter 2026 Financial ResultsPR NewswireSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical
- 3mo agoINBXInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 MillionPR NewswireInhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel...
- 4mo agoINBXInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel...
- 6mo agoINBXInhibrx Reports First Quarter 2026 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2026. The...
- 6mo agoINBXInhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 MonotherapyPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel...
- 6mo agoINBXInhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCCPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 6mo agoINBXInhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel...
- 6mo agoINBXInhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal CancerPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 7mo agoINBXInhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025....
- 8mo agoINBXInhibrx Announces Participation in Upcoming Scientific ConferencePR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic...
- 11mo agoINBXInhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) ProgramPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 12mo agoINBXInhibrx Reports Third Quarter 2025 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the...
- 1y agoINBXInhibrx Announces Participation in Upcoming Scientific ConferencesPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic...
- 1y agoINBXInhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion CohortsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 1y agoINBXInhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion CohortsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 1y agoINBXInhibrx Reports Second Quarter 2025 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the...
- 1y agoINBXInhibrx Reports First Quarter 2025 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the...
- 1y agoINBXInhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and PresidentPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage ...
- 1y agoINBXInhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024....
- 1y agoINBXInhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal CancerPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics...
- 1y agoINBXInhibrx Biosciences Announces Loan Agreement with Oxford FinancePR NewswireInhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials,...
- 1y agoINBXInhibrx Biosciences Reports Third Quarter 2024 Financial ResultsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024....
- 2y agoINBXInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a ...
- 2y agoINBXInhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsPR NewswireInhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical...
- 2y agoINBXInhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiPR NewswireInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders...
- 2y agoINBXInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffPR NewswireInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that in connection with the previously announced distribution by the...
- 2y agoINBXInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerPR NewswireInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") today announced that it has set a record date of May 17, 2024 (the "Record Date") for the...
- 2y agoINBXInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsPR NewswireInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with three clinical programs in development and a strong...
- 2y agoDOCBATLKAMNINBXKuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
- 2y agoINBXSNYInhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2BPR NewswireInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") and Sanofi (Nasdaq: SNY) ("Sanofi") today announced that the companies have entered into a ...
- 3y agoINBXInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsPR NewswireInhibrx, Inc. (Nasdaq: INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong...
- 3y agoINBXInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaPR NewswireInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, ...
- 3y agoINBXInhibrx Announces Participation in Upcoming Scientific ConferencesPR NewswireInhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, ...
- 3y agoINBXInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaPR NewswireSAN DIEGO, Sept. 19, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that Chiesi
- 3y agoINBXInhibrx Announces $200 Million Private Placement FinancingPR NewswireSAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and
- 3y agoINBXInhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsPR NewswireSAN DIEGO, Aug. 7, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), or Inhibrx, or the Company, a biopharmaceutical company with four programs in ongoing clinical trials and a strong emerging pipeline, today reported
- 3y agoINBXOpen Label Extension Study of INBRX-101 in Adults With AATD Emphysema - NCT05897424ClinicalTrials.govLong-term safety and tolerability, Change in lung density by quantitative computerized tomography (CT), Trough INBRX-101 concentration changes, (and 6 more...)
- 3y agoINBXInhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin DeficiencyPR NewswireSAN DIEGO, May 30, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that the U.S.
- 3y agoINBXInhibrx Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsPR NewswireSAN DIEGO, May 8, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), or Inhibrx, or the Company, a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported
- 3y agoINBXInhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist TrialsPR NewswireSAN DIEGO, April 26, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has
- 3y agoINBXInhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial ResultsPR NewswireSAN DIEGO, March 6, 2023 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline,
- 3y agoINBXNorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical CandidatesPR NewswireBELOIT, Wis. and SAN DIEGO, Jan. 4, 2023 /PRNewswire/ -- NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic
- 3y agoINBXNorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical CandidatesBusiness WireNorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, and Inhibrx, Inc.
- 3y agoINBXInhibrx Announces Participation in Upcoming Investor ConferencePR NewswireSAN DIEGO, Nov. 18, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be
- 3y agoINBXInhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-109 for the Treatment of ChondrosarcomaPR NewswireSAN DIEGO, Nov. 16, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced updated
- 4y agoINBXInhibrx Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsPR NewswireSAN DIEGO, Nov. 7, 2022 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biopharmaceutical company with four clinical programs in development and a strong emerging pipeline, today reported financial results for the